NP 001

Drug Profile

NP 001

Alternative Names: NP001

Latest Information Update: 13 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Neuraltus Pharmaceuticals
  • Class Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Immunomodulators; Macrophage modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis
  • Preclinical Alzheimer's disease; Ataxia telangiectasia; Dementia; Parkinson's disease

Most Recent Events

  • 12 Jul 2017 Neuraltus Pharmaceuticals completes enrolment in a phase II trial for Amyotrophic lateral sclerosis in USA and Canada
  • 09 Jun 2017 University of Hawaii and Neuraltus Pharmaceuticals plan a phase II trial for Alzheimer disease (In adults, In elderly) (NCT03179501)
  • 22 Sep 2016 Neuraltus Pharmaceuticals initiates a phase II trial for Amyotrophic lateral sclerosis in USA (NCT02794857)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top